ReviewCancer growth and metastasis2017
Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents.
Review in Cancer growth and metastasis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Ductal Adenocarcinoma.Cancer research · 2024Article
- Enhancement of Tumorigenicity, Spheroid Niche, and Drug Resistance of Pancreatic Cancer Cells in Three-Dimensional Culture System.Journal of Cancer · 2024Article
- Integrated Bioinformatics Analysis Identifies Crucial Biochemical Processes Shared between Pancreatitis and Pancreatic Ductal Adenocarcinoma.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Estimating Metastatic Risk of Pancreatic Ductal Adenocarcinoma at Single-Cell Resolution.International journal of molecular sciences · 2022Article
- Article
- Role of epithelial-mesenchymal transition in chemoresistance in pancreatic ductal adenocarcinoma.World journal of clinical cases · 2021Review
- Exploring the Crosstalk between Inflammation and Epithelial-Mesenchymal Transition in Cancer.Mediators of inflammation · 2021Review
- Epithelial-Mesenchymal Transition and Its Regulation Mechanisms in Pancreatic Cancer.Frontiers in oncology · 2021Review
- MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer.International journal of molecular sciences · 2020Review
- Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance.Cellular oncology (Dordrecht, Netherlands) · 2020Review
- Loss of Wasl improves pancreatic cancer outcome.JCI insight · 2020Article
- A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma.Small (Weinheim an der Bergstrasse, Germany) · 2020Article
- Research Progress of Pancreas-Related Microorganisms and Pancreatic Cancer.Frontiers in oncology · 2020Review
- Gemcitabine induces Epithelial-to-Mesenchymal Transition in patient-derived pancreatic ductal adenocarcinoma xenografts.American journal of translational research · 2019Article
- Endogenous Anti-Inflammatory Very-Long-Chain Dicarboxylic Acids: Potential Chemopreventive Lipids.Metabolites · 2018Article
- PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer.Oncotarget · 2018Article
- Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment.Oncotarget · 2018Review
- Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development.Frontiers in immunology · 2017Review
- Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and one of the most lethal human cancers. Inflammation is a critical component in PDAC initiation and progression. Inflammation also contributes to the aggressiveness of PDAC indirectly via induction of epithelial-mesenchymal transition (EMT), altogether leading to enhanced resistance to chemotherapy and poor survival rates. This review gives an overview of the key pro-inflammatory signaling pathways involved in PDAC pathogenesis and discusses the role of inflammation in induction of EMT and development of chemoresistance in patients with PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.